Risultati di ricerca
7 set 2022 · Dr. Jerry McMahon added: “STORM is well positioned to fulfil its ambition of becoming the global leader in the field of RME. STORM’s first-in-class clinical candidate STC-15, an orally-bioavailable, highly selective METTL3 inhibitor, is on schedule to start initial clinical studies in solid tumors in 2022 and will be the first first-ever RME inhibitor molecule to enter clinical development.
Jerry McMahon is on Facebook. Join Facebook to connect with Jerry McMahon and others you may know. Facebook gives people the power to share and makes the world more open and connected.
Jerry McMahon is President/CEO at Storm Therapeutics Ltd. See Jerry McMahon's compensation, career history, education, & memberships.
Dr. Jerry McMahon added: "STORM is well positioned to fulfil its ambition of becoming the global leader in the field of RME. STORM's first-in-class clinical candidate STC-15, an orally-bioavailable, highly selective METTL3 inhibitor, is on schedule to start initial clinical studies in solid tumors in 2022 and will be the first first-ever RME inhibitor molecule to enter clinical development.
Jerry McMahon is on Facebook. Join Facebook to connect with Jerry McMahon and others you may know. Facebook gives people the power to share and makes the world more open and connected.
2 nov 2023 · Gerald Vincent McMahon, Sr. "Jerry," 90, of Onondaga Hill passed away on All Saints Day, Wednesday, November 1, 2023, with his loving wife of 64 years, Margaret Noonan McMahon, by his side. Jerry was a devoted husband, father, grandfather, great grandfather and older brother. He led his family by his example of faith, provided for them through ...
7 set 2022 · Dr. Jerry McMahon added: “STORM is well positioned to fulfil its ambition of becoming the global leader in the field of RME. STORM’s first-in-class clinical candidate STC-15, an orally-bioavailable, highly selective METTL3 inhibitor, is on schedule to start initial clinical studies in solid tumors in 2022 and will be the first first-ever RME inhibitor molecule to enter clinical development.
